Minniti G, Jaffrain-Rea M-L, Esposito V, Santoro A, Tamburrano G, Cantore G
Department of Neurological Sciences, Neuromed Institute, RCSS, Via Atinense 18, 86077 Pozzili (IS), Italy.
Endocr Relat Cancer. 2003 Dec;10(4):611-9. doi: 10.1677/erc.0.0100611.
Criteria to define the biochemical remission of acromegaly following surgery have changed over the years, and the current use of stringent criteria needs a critical re-evaluation of the surgical results. On the other hand, few data are currently available concerning the possible impact of pituitary surgery on the quality of life of operated acromegalic patients. In this prospective study, we wished to evaluate the initial outcome and long-term recurrence rate in a large series of acromegalic patients operated on by transsphenoidal surgery (TSS), to carefully analyse predictive factors for surgical outcome and to point out possible additional effects of surgery in these patients. Ninety-two out of 98 operated patients could be considered for follow-up. Biochemical remission was strictly defined as plasma GH levels <1 ng/ml during an oral glucose tolerance test (OGTT) and normalisation of age-related IGF-I levels. Hormonal assessment, including an OGTT, was performed 6 months following surgery and then annually to evaluate pituitary function. Fifty-five per cent of patients achieved a biochemical remission of acromegaly. The remission rate at 6 months was 80% for patients with microadenoma and 50% for macroadenoma. Univariate analysis showed that a large extrasellar extension, preoperative high GH levels and dural invasion were correlated with a poor outcome of surgery while, according to multivariate analysis, only invasion of cavernous sinus and preoperative GH levels > 10 ng/ml were independent negative predictors. Mortality was 0% and the overall complication rate was about 10%. Pituitary function worsened in five patients but improved in 16 out of 30 patients with preoperative pituitary defects. No recurrence was observed during a median follow-up of about 8 years. We conclude that TSS is able to achieve a biochemical remission in more than half of acromegalic patients, and that the current criteria for remission seem to indicate a cure in most cases.
多年来,用于定义肢端肥大症术后生化缓解的标准不断变化,而目前严格标准的使用需要对手术结果进行批判性重新评估。另一方面,目前关于垂体手术对接受手术的肢端肥大症患者生活质量可能产生的影响的数据很少。在这项前瞻性研究中,我们希望评估大量经蝶窦手术(TSS)治疗的肢端肥大症患者的初始结局和长期复发率,仔细分析手术结局的预测因素,并指出手术对这些患者可能产生的其他影响。98例接受手术的患者中有92例可纳入随访。生化缓解被严格定义为口服葡萄糖耐量试验(OGTT)期间血浆GH水平<1 ng/ml且年龄相关的IGF-I水平正常化。术后6个月进行包括OGTT在内的激素评估,然后每年进行一次以评估垂体功能。55%的患者实现了肢端肥大症的生化缓解。微腺瘤患者6个月时的缓解率为80%,大腺瘤患者为50%。单因素分析显示,鞍外广泛扩展、术前GH水平高和硬膜侵犯与手术预后不良相关,而根据多因素分析,只有海绵窦侵犯和术前GH水平>10 ng/ml是独立的阴性预测因素。死亡率为0%,总体并发症发生率约为10%。5例患者垂体功能恶化,但30例术前有垂体缺陷的患者中有16例垂体功能改善。在约8年的中位随访期内未观察到复发。我们得出结论,TSS能够使超过一半的肢端肥大症患者实现生化缓解,并且目前的缓解标准似乎在大多数情况下表明治愈。